All In Biotech

Drug Trial Radar · NCT01866111

A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures

A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Dose-Response Trial of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures, With Optional Open-Label Extension

Last checked: Nov 19, 2026Latest source record: Jun 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 437 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

437

Actual

Start

Jul 31, 2013

Primary completion

Apr 5, 2021

Study completion Oct 31, 2021

Sponsor

Lead sponsor
SK Life Science, Inc.Industry
Sponsor type
Industry
First posted
May 31, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, double-blind, randomized, placebo-controlled dose response study, with an 8-week prospective baseline and an 18 week double-blind treatment period (including a 6-week titration phase and 12 week maintenance phase), followed by a 3-week blinded study drug taper period (for subjects leaving the study) or a 2-week blinded conversion period (for subjects who will participate in the open-label extension). The primary objective of this study is to determine the effective dose range of YKP3089 as adjunctive therapy for the treatment of partial seizures. The trial will also evaluate the safety and tolerability of YKP3089 in the partial epilepsy population.

Conditions

  • Partial Epilepsy

Interventions

  • YKP3089Drug

  • PlaceboDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent Change From Baseline in Partial-onset Seizure Frequency Per 28 DaysTime frame: baseline and 18 weeks

Locations

67 sites in 15 countries. Site status is shown where the registry gives one.

  • St. Joseph's Hospital and Medical Center - Barrow Neurology Clinics

    Phoenix, Arizona

  • Clinical Trials, Inc.

    Little Rock, Arkansas

  • Kaiser Permanente, Department of Neurology

    Anaheim, California

  • Neuro-Pain Medical Center

    Fresno, California

  • West Los Angeles VA Medical Center, Clinical Research Center

    Los Angeles, California

  • Neuroresearch, Inc. - Torrance

    Torrance, California

  • Neuroresearch II, Inc.

    Ventura, California

  • Bradenton Research Center, Inc.

    Bradenton, Florida

  • Lovelace Scientific Resources, Inc.

    Sarasota, Florida

  • Consultants in Epilepsy & Neurology, PLLC

    Boise, Idaho

  • Johns Hopkins University

    Baltimore, Maryland

  • Mid-Atlantic Epilepsy and Sleep Center

    Bethesda, Maryland

  • Neurology Clinic PC

    Waldorf, Maryland

  • The Comprehensive Epilepsy Care Center for Children and Adults

    St Louis, Missouri

  • Northeast Regional Epilepsy Group

    Hackensack, New Jersey

  • NYU Comprehensive Epilepsy Center

    New York, New York

  • The Neurological Institute, PA

    Charlotte, North Carolina

  • Thomas Jefferson Comprehensive Epilepsy Center

    Philadelphia, Pennsylvania

  • Vanderbilt Epilepsy Clinic

    Nashville, Tennessee

  • Austin Epilepsy Care Center

    Austin, Texas

  • University of Virginia Comprehensive Epilepsy Program

    Charlottesville, Virginia

  • Institute of Neurological Sciences, Prince of Wales Hospital

    Randwick, New South Wales, Australia

  • Monash Medical Centre

    Clayton, Victoria, Australia

  • St. Vincent's Hospital (Melbourne)

    Fitzroy, Victoria, Australia

  • Epilepsy Research Centre, Melbourne Brain Centre

    Heidelberg, Victoria, Australia

  • The Royal Melbourne Hospital

    Melbourne, Victoria, Australia

  • University Multiprofile Hpspital for Active Treatment "Sveti Georgi" EAD, Clinic of Neurological Diseases

    Plovdiv, Bulgaria

  • "First Multiprofile Hospital for Active Treatment - Sofia" EAD, Neurology Clinic

    Sofia, Bulgaria

  • University of Multiprofile Hospital for Active Treatment "Aleksandrovska" EAD, Clinic of Neurological Diseases

    Sofia, Bulgaria

  • Fakultní nemocnice Ostrava, Neurologická klinika

    Ostrava, Czechia

  • Mediscan Group, s.r.o

    Prague, Czechia

  • Fakultni nemocnice v Motole, Neurologická klinika

    Prague, Czechia

  • CHU - Service Neurophysiologie Clinique

    Dijon, France

  • Hôpital Central - CHU de Nancy - Service de Neurologie

    Nancy, France

  • Epilepsiezentrum Berlin- Bradenburg, Epilepsieklinik "Tabor"

    Bernau bei Berlin, Germany

  • Krankenhaus Mara gGmbH, Epilepsiezentrum Bethel

    Bielefeld, Germany

  • Epilepsiezentrum Kork

    Kehl, Germany

  • Országos Klinikai Idegtudományi Intézet

    Budapest, Hungary

  • Department of Neurology, Hadassah University Hospital Ein Kerem, Kiryat Hadassah

    Jerusalem, Israel

  • Western Galilee Hospital, Department of Neurology

    Nahariya, Israel

Showing 40 of 67 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.